Exact Mass: 624.3665

Dauricine

C38H44N2O6 (624.3199)

Dauricine is a bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). It has a role as a plant metabolite. It is a tertiary amino compound, a member of phenols, an aromatic ether, a member of isoquinolines and a bisbenzylisoquinoline alkaloid. Dauricine is a natural product found in Nelumbo nucifera, Menispermum canadense, and Menispermum dauricum with data available. A bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer[1]. Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer[1].

Caribenolide I

C33H52O11 (624.3509)

Neferine

C38H44N2O6 (624.3199)

Neferine is found in coffee and coffee products. Neferine is an alkaloid from the seed embryo of Nelumbo nucifera (East Indian lotus Alkaloid from the seed embryo of Nelumbo nucifera (East Indian lotus). Neferine is found in coffee and coffee products. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.

PG(a-13:0/i-12:0)

C31H61O10P (624.4002)

PG(a-13:0/i-12:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(a-13:0/i-12:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

PG(i-12:0/a-13:0)

C31H61O10P (624.4002)

PG(i-12:0/a-13:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-12:0/a-13:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of anteisotridecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

PG(i-12:0/i-13:0)

C31H61O10P (624.4002)

PG(i-12:0/i-13:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-12:0/i-13:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isotridecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

PG(i-13:0/i-12:0)

C31H61O10P (624.4002)

PG(i-13:0/i-12:0) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(i-13:0/i-12:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis.

Cyclo(D-Trp-D-Asp-Pro-D-Ile-Leu)

C32H44N6O7 (624.3271)

Dauricine

C38H44N2O6 (624.3199)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C33H53O9P (624.3427)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

C33H53O9P (624.3427)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

C33H53O9P (624.3427)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

C33H53O9P (624.3427)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

C33H53O9P (624.3427)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427)

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

C33H53O9P (624.3427)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Neferin

C38H44N2O6 (624.3199)

Neferine is a member of isoquinolines. Neferine is a natural product found in Nelumbo nucifera with data available. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.

Superstolide A

C36H52N2O7 (624.3774)

Antibiotic MG 398HF9A

C31H52N4O9 (624.3734)

Linckoside F

C34H56O10 (624.3873)

Simplexin E

C33H52O11 (624.3509)

23-O-beta-D-Glucopyranosyl-25-methyldolichosterone

C34H56O10 (624.3873)

Methyl glucosyl-3,4-dehydro-apo-8-lycopenate

C37H52O8 (624.3662)

24-epipetunioside C

C33H52O11 (624.3509)

Neothalibrine

C38H44N2O6 (624.3199)

teikagenin-3-O-beta-D-digitalosyl-20-O-beta-D-canaroside|teikaside A-Ia

C34H56O10 (624.3873)

Ferulinolone

C41H52O5 (624.3815)

podecdysone B 25-O-beta-D-glucopyranoside

C33H52O11 (624.3509)

26-O-beta-D-glucopyranosyl-22alpha-furosta-5,25(27)-diene-1beta,3beta,11alpha,22alpha,26-pentaol|26-[(beta-D-glucopyranosyl)oxy]-22alpha-hydroxyfurosta-5,25(27)-diene-1beta,3beta,11alpha-triol|helleboroside B

C33H52O11 (624.3509)

desulfated echinasteroside A

C34H56O10 (624.3873)

(25R)-spirost-7-ene-2alpha,3beta,5alpha,9alpha-tetrol 3-O-beta-D-glucopyranoside

C33H52O11 (624.3509)

Pisopowiarine

C38H44N2O6 (624.3199)

palmerolide D

C36H52N2O7 (624.3774)

Ecdysterone 2,3-acetonide 22-O-benzoate

C37H52O8 (624.3662)

Acobretine D

C35H48N2O8 (624.341)

citrinadin A

C35H52N4O6 (624.3887)

3-O-stearyl-3,4,5,7-tetra-O-methylquercetin

C37H52O8 (624.3662)

14-deoxy-14alpha,15alpha-epoxyponasteroside A|brainesteroside A

C33H52O11 (624.3509)

solanolactoside B

C33H52O11 (624.3509)

THALIBRINE

C38H44N2O6 (624.3199)

Pisopowetine

C38H44N2O6 (624.3199)

3-O-beta-D-(2,3-di-O-methyl-beta-xylopyranosyl)-22E-27-nor-24-methyl-5alpha-cholesta-4,22-diene-3beta,6beta,8,15alpha,16beta,26-hexaol|leviusculoside J

C34H56O10 (624.3873)

Anthogorgiene K

C44H48O3 (624.3603)

(25S)-3beta,27-dihydroxy-5alpha-spirostan-6alpha-yl-O-beta-D-glucopyranoside

C34H56O10 (624.3873)

mandelalide A

C33H52O11 (624.3509)

(5alpha)-pregna-16-en-3beta-ol-20-one 6-O-[alpha-L-rhamnopyranosyl-(1?3)-beta-D-quinovopyranoside]|torvpregnanoside A

C33H52O11 (624.3509)

7-Deepoxy,6-hydroxy,7-chloro,2,3,4,5-tetrahydro-Huratoxin

C34H53ClO8 (624.3429)

3-(3,4-Dihydroxybenzoyl)-2,3,27-Thrihydroxy-12-lupen-28-oic acid

C37H52O8 (624.3662)

C34H56O10

C34H56O10 (624.3873)

Sporidesmolide-III

C32H56N4O8 (624.4098)

(25S)-22alpha,25-epoxy-3beta,11alpha-dihydroxyfurost-5-en-26-yl beta-D-glucopyranoside

C33H52O11 (624.3509)

3,4a,5,7,6,8-Hexamethoxy-4,6,7-triisopropyl-3,4a,4,9a-tetrahydrospiro[9H-xanthene-1(2H),2-[2H]-1-benzopyran]-2-one

C36H48O9 (624.3298)

calogenin 3-O-beta-D-digitalopyranoside-20-O-beta-D-canaropyranoside

C34H56O10 (624.3873)

Lys Leu His Val Asp

C28H48N8O8 (624.3595)

Leu Asp Val Lys His

C28H48N8O8 (624.3595)

Leu Thr Ser Lys Tyr

C29H48N6O9 (624.3483)

Phe Phe Arg Arg

C30H44N10O5 (624.3496)

Phe Arg Phe Arg

C30H44N10O5 (624.3496)

Phe Arg Arg Phe

C30H44N10O5 (624.3496)

Met Arg Arg Tyr

C26H44N10O6S (624.3166)

Met Arg Tyr Arg

C26H44N10O6S (624.3166)

Met Tyr Arg Arg

C26H44N10O6S (624.3166)

Arg Phe Phe Arg

C30H44N10O5 (624.3496)

Arg Phe Arg Phe

C30H44N10O5 (624.3496)

Arg Met Arg Tyr

C26H44N10O6S (624.3166)

Arg Met Tyr Arg

C26H44N10O6S (624.3166)

Arg Arg Phe Phe

C30H44N10O5 (624.3496)

Arg Arg Met Tyr

C26H44N10O6S (624.3166)

Arg Arg Tyr Met

C26H44N10O6S (624.3166)

Arg Tyr Met Arg

C26H44N10O6S (624.3166)

Arg Tyr Arg Met

C26H44N10O6S (624.3166)

Tyr Met Arg Arg

C26H44N10O6S (624.3166)

Tyr Arg Met Arg

C26H44N10O6S (624.3166)

Tyr Arg Arg Met

C26H44N10O6S (624.3166)

PG(12:0/13:0)

C31H61O10P (624.4002)

PG(13:0/12:0)

C31H61O10P (624.4002)

PI(20:2(11Z,14Z)/0:0)

C29H53O12P (624.3274)

PG 25:0

C31H61O10P (624.4002)

LPI 20:2

C29H53O12P (624.3274)

PHOHA-PG

C29H53O12P (624.3274)

OG-PG

C29H53O12P (624.3274)

Brainesteroside A

C33H52O11 (624.3509)

Mantuoluoside A

C34H56O10 (624.3873)

Mantuoluoside B

C34H56O10 (624.3873)

Spongipregnoloside A

C33H52O11 (624.3509)

ST 33:2_O7

C33H52O11 (624.3509)

Aspacoside A

C33H52O11 (624.3509)

Aspacoside B

C33H52O11 (624.3509)

Linkckoside F

C34H56O10 (624.3873)

1-(D-Mannosyloxy)-3,4-didenhydro-1,2-dihydro-8-apolycopen-8-oic acid

C37H52O8 (624.3662)

Methyl mannosyl-3,4-dehydro-apo-8-lycopenoate

C37H52O8 (624.3662)

Methyl glucosyl-3,4-dehydro-apo-8-lycopenoate

C37H52O8 (624.3662)

JKC-301

C32H44N6O7 (624.3271)

Cicloxolone

C38H56O7 (624.4026)

Tirilazad

C38H52N6O2 (624.4152)

C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents > D000975 - Antioxidants N - Nervous system

HCV-IN-30

C36H44N6O4 (624.3424)

2-ethylhexane-1,3-diolate,hydron,titanium(4+)

C32H64O8Ti---- (624.408)

Chol-6-en-24-oic acid, 3,7-bis[(trimethylsilyl)oxy]-, phenylmethyl ester, (3α,5β)-

C37H60O4Si2 (624.403)

Testosterone enantate benzilic acid hydrazone

C40H52N2O4 (624.3927)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

3-[(21S,22S)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-12-(hydroxymethyl)-17,19,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

C37H44N4O5 (624.3312)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C33H53O9P (624.3427)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C33H53O9P (624.3427)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C33H53O9P (624.3427)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

C33H53O9P (624.3427)

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C33H53O9P (624.3427)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

C33H53O9P (624.3427)

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

C33H53O9P (624.3427)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[(3R,9S,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[(3R,9R,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[[(3R,9R,10R)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[(3R,9R,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[(3R,9S,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3S,9R,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[[(3R,9R,10S)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[[(3R,9R,10R)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[[(3S,9S,10R)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[[(3S,9S,10S)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[(3S,9R,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[[(3S,9S,10S)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[(3S,9S,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3523)

N-[[(3R,9S,10R)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[(3R,9S,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3S,9S,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3S,9S,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3S,9S,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3S,9R,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[[(3R,9S,10S)-16-[[4-(dimethylamino)-1-oxobutyl]amino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzamide

C35H52N4O6 (624.3887)

N-[(3R,9R,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3R,9S,10S)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

N-[(3R,9R,10R)-9-[[[4-(dimethylamino)-1-oxobutyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C35H52N4O6 (624.3887)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (11Z,14Z)-icosa-11,14-dienoate

C29H53O12P (624.3274)

Smgdg O-17:2_3:0

C29H52O12S (624.3179)

Smgdg O-18:2_2:0

C29H52O12S (624.3179)

Smgdg O-16:2_4:0

C29H52O12S (624.3179)

PEtOH 29:5

C34H57O8P (624.3791)

PMeOH 12:0_18:5

C34H57O8P (624.3791)

PMeOH 14:1_16:4

C34H57O8P (624.3791)

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C34H56O10 (624.3873)

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C34H56O10 (624.3873)

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C34H56O10 (624.3873)

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C34H56O10 (624.3873)

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] docosanoate

C31H61O10P (624.4002)

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] icosanoate

C31H61O10P (624.4002)

[1-[(2-Acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] tricosanoate

C31H61O10P (624.4002)

[1-[(2-Hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] nonadecanoate

C31H61O10P (624.4002)

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] hexadecanoate

C31H61O10P (624.4002)

[1-[(2-Butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] henicosanoate

C31H61O10P (624.4002)

[1-[(2-Heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] octadecanoate

C31H61O10P (624.4002)

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] heptadecanoate

C31H61O10P (624.4002)

[1-[(2-Dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] tridecanoate

C31H61O10P (624.4002)

[1-[(2-Decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] pentadecanoate

C31H61O10P (624.4002)

[1-Hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] tetradecanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] hexadecanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] heptadecanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] icosanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] docosanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] nonadecanoate

C31H61O10P (624.4002)

[1-Butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] henicosanoate

C31H61O10P (624.4002)

[1-Acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] tricosanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] octadecanoate

C31H61O10P (624.4002)

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C34H57O8P (624.3791)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] tridecanoate

C31H61O10P (624.4002)

[1-Decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] pentadecanoate

C31H61O10P (624.4002)

[1-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] tetradecanoate

C31H61O10P (624.4002)

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C34H57O8P (624.3791)

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C34H57O8P (624.3791)

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C34H57O8P (624.3791)

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C34H57O8P (624.3791)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] tridecanoate

C31H61O10P (624.4002)

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] pentadecanoate

C31H61O10P (624.4002)

[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C34H57O8P (624.3791)

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C34H57O8P (624.3791)

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C34H57O8P (624.3791)

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C34H57O8P (624.3791)

[1-[(9E,12E)-pentadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H57O8P (624.3791)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] tetradecanoate

C31H61O10P (624.4002)

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] pentadecanoate

C31H61O10P (624.4002)

[1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H57O8P (624.3791)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] tetradecanoate

C31H61O10P (624.4002)

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H55NO8P+ (624.3665)

2-[[2-butanoyloxy-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H59NO7P+ (624.4029)

2-[[3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H59NO7P+ (624.4029)

2-[[2-acetyloxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H59NO7P+ (624.4029)

CID 131823275

C31H61O10P (624.4002)

1-(9Z-octadecenoyl)-2-glutaryl-sn-glycero-3-phospho-(1-sn-glycerol)

C29H53O12P (624.3274)

Spongipregnoloside B

C33H52O11 (624.3509)

1-(11Z,14Z-eicosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C29H53O12P (624.3274)

MGDG O-25:5;O

C34H56O10 (624.3873)

SMGDG O-20:2

C29H52O12S (624.3179)

SQDG 20:1

C29H52O12S (624.3179)

DGMG 14:1

C29H52O14 (624.3357)

SQMG 21:1

C30H56O11S (624.3543)

DGGA 24:4

C33H52O11 (624.3509)

MGGA 25:4

C34H56O10 (624.3873)

PA O-14:1/18:4

C35H61O7P (624.4155)

PA O-31:6;O

C34H57O8P (624.3791)

PA O-32:5

C35H61O7P (624.4155)

PA P-14:0/18:4

C35H61O7P (624.4155)

PA P-14:0/18:4 or PA O-14:1/18:4

C35H61O7P (624.4155)

PA P-18:1/13:4;O

C34H57O8P (624.3791)

PA P-32:4

C35H61O7P (624.4155)

PA P-32:4 or PA O-32:5

C35H61O7P (624.4155)

PA 18:3/12:3;O

C33H53O9P (624.3427)

PA 22:5/8:1;O

C33H53O9P (624.3427)

PA 30:6;O

C33H53O9P (624.3427)

PA 11:0_20:5

C34H57O8P (624.3791)

PA 31:5

C34H57O8P (624.3791)

PG O-16:0/7:3;O3

C29H53O12P (624.3274)

PG O-16:0/8:2;O2

C30H57O11P (624.3638)

PG O-16:0/9:1;O

C31H61O10P (624.4002)

PG O-20:0/5:1;O

C31H61O10P (624.4002)

PG O-23:3;O3

C29H53O12P (624.3274)

PG O-24:2;O2

C30H57O11P (624.3638)

PG O-25:1;O

C31H61O10P (624.4002)

PG P-16:0/7:2;O3

C29H53O12P (624.3274)

PG P-16:0/8:1;O2

C30H57O11P (624.3638)

PG P-20:0/4:1;O2

C30H57O11P (624.3638)

PG 14:1/9:1;O2

C29H53O12P (624.3274)

PG 16:0/7:2;O2

C29H53O12P (624.3274)

PG 16:0/8:1;O

C30H57O11P (624.3638)

PG 18:1/5:1;O2

C29H53O12P (624.3274)

PG 20:0/4:1;O

C30H57O11P (624.3638)

PG 24:1;O

C30H57O11P (624.3638)

PG 10:0_15:0

C31H61O10P (624.4002)

PG 11:0_14:0

C31H61O10P (624.4002)

PG 12:0_13:0

C31H61O10P (624.4002)

PG 21:0/4:0

C31H61O10P (624.4002)

PG 23:0/2:0

C31H61O10P (624.4002)

PI O-16:1/4:1

C29H53O12P (624.3274)

PI O-16:2/4:0

C29H53O12P (624.3274)

PI O-18:2/2:0

C29H53O12P (624.3274)

PI O-20:2

C29H53O12P (624.3274)

PI P-16:0/4:1

C29H53O12P (624.3274)

PI P-16:0/4:1 or PI O-16:1/4:1

C29H53O12P (624.3274)

PI P-16:1/4:0

C29H53O12P (624.3274)

PI P-16:1/4:0 or PI O-16:2/4:0

C29H53O12P (624.3274)

PI P-18:1/2:0

C29H53O12P (624.3274)

PI P-18:1/2:0 or PI O-18:2/2:0

C29H53O12P (624.3274)

PI P-20:1

C29H53O12P (624.3274)

PI P-20:1 or PI O-20:2

C29H53O12P (624.3274)

LPEth 30:5

C35H61O7P (624.4155)

LPM 31:5

C35H61O7P (624.4155)

PEth 28:6;O

C33H53O9P (624.3427)

PEth 29:5

C34H57O8P (624.3791)

PM 29:6;O

C33H53O9P (624.3427)

PM 30:5

C34H57O8P (624.3791)

ST 27:2;O5;GlcA

C33H52O11 (624.3509)

ST 28:1;O4;GlcA

C34H56O10 (624.3873)

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)

methyl (2e,4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,11,15,19,23-hexamethyl-23-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C37H52O8 (624.3662)

(1s,2s,4s,6r,7s,8r,9s,11r,12s,13r,14r,16r)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

C33H52O11 (624.3509)

1-(2,3-dihydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

C33H52O11 (624.3509)

(2s,4'as,9'as)-4',6',7-triisopropyl-3',4'a,5',6,7',8-hexamethoxy-3,4,9',9'a-tetrahydrospiro[1-benzopyran-2,1'-xanthen]-2'-one

C36H48O9 (624.3298)

5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)

(1r,3r,9r,10r,13r,15r,21s,23r)-23-{[(2r,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-13-hydroxy-15-(hydroxymethyl)-3,10-dimethyl-16,25,26-trioxatricyclo[19.3.1.1⁹,¹²]hexacosa-4,6,18-trien-17-one

C33H52O11 (624.3509)

n-(1-{[(4e,10e,12z)-6,22-dihydroxy-16-methoxy-5,7-dimethyl-18-oxo-25-oxa-19-azatetracyclo[12.9.2.0¹⁵,¹⁹.0²⁰,²⁴]pentacosa-1(24),4,10,12,20,22-hexaen-8-yl]oxy}-1-oxopropan-2-yl)-4-methylpentanimidic acid

C35H48N2O8 (624.341)

5-methyl-n-[(2r)-1-oxo-1-{[(5r,13s,14r,15r)-3,15,22-trihydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}propan-2-yl]hexanimidic acid

C36H52N2O7 (624.3774)

(1s)-1-{[4-(5-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-methoxyphenoxy)phenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C38H44N2O6 (624.3199)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-5-hydroxy-3,4-dimethoxyoxan-2-yl]oxy}-1-[(2r,3e)-7-hydroxy-5-methylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-(4-{[(1s)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)phenol

C38H44N2O6 (624.3199)

6-(2,3-dihydroxy-6-methylheptan-2-yl)-13-hydroxy-7,11-dimethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

C33H52O11 (624.3509)

(2r,3ar,6s,8r,9ar,10as)-7'-(3,3-dimethyloxirane-2-carbonyl)-2',10a-dihydroxy-1,1,6-trimethyl-3a-(methylamino)-3,4,6,7,8,9,9a,10-octahydrospiro[cyclopenta[b]quinolizine-2,3'-indol]-8-yl (2s)-2-(dimethylamino)-3-methylbutanoate

C35H52N4O6 (624.3887)

7-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-1-(7-hydroxy-6-methyl-5-methylideneheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14s)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)

1-[(3-{4-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenoxy}-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C38H44N2O6 (624.3199)

2-{4-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenoxy}-4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

C38H44N2O6 (624.3199)

(2r,3r,4s,5s,6r)-2-{[(1r,3as,3br,5ar,7s,9as,9bs,11as)-1-[(1s)-1-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}ethyl]-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C34H56O10 (624.3873)

2-(4-{14,16-dihydroxy-6-methoxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-6-yl}-2-methylbutoxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O10 (624.3873)

7-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-1-(7-hydroxy-5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)

4',6',7-triisopropyl-3',4'a,5',6,7',8-hexamethoxy-3,4,9',9'a-tetrahydrospiro[1-benzopyran-2,1'-xanthen]-2'-one

C36H48O9 (624.3298)

(2s,4s,6s,7r,10r,11r,13s,14r,16r)-6-[(2r,3r)-2,3-dihydroxy-6-methylheptan-2-yl]-13-hydroxy-7,11-dimethyl-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

C33H52O11 (624.3509)

2-[(1-{1-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]ethyl}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-4-methoxy-6-methyloxane-3,5-diol

C34H56O10 (624.3873)

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)

7-[(5-hydroxy-3,4-dimethoxyoxan-2-yl)oxy]-1-(7-hydroxy-5-methylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

methyl 2,6,11,15,19,23-hexamethyl-23-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C37H52O8 (624.3662)

(2r,3r,4s,5s,6r)-2-{[(1s,3as,3br,7s,9ar,9bs,11ar)-1-[(1s)-1-{[(2r,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}ethyl]-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C34H56O10 (624.3873)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-5-hydroxy-3,4-dimethoxyoxan-2-yl]oxy}-1-[(2r,3e,5r)-7-hydroxy-5-methylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

5-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-2-({6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl}oxy)phenol

C38H44N2O6 (624.3199)

5'-(5,6-dihydroxy-5,6-dimethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3s,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O11 (624.3509)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-1-[(2r,3e,5r,6s)-7-hydroxy-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

(10'e,14'e,16'e)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7'-dioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 3-methylbut-2-enoate

C37H52O8 (624.3662)

(2r,3ar,6s,8r,9ar,10as)-7'-[(2r)-3,3-dimethyloxirane-2-carbonyl]-2',10a-dihydroxy-1,1,6-trimethyl-3a-(methylamino)-3,4,6,7,8,9,9a,10-octahydrospiro[cyclopenta[b]quinolizine-2,3'-indol]-8-yl (2s)-2-(dimethylamino)-3-methylbutanoate

C35H52N4O6 (624.3887)

2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxochromen-3-yl octadecanoate

C37H52O8 (624.3662)

(1r)-1-{[3-(4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenoxy)-4-methoxyphenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C38H44N2O6 (624.3199)

4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-({6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl}oxy)phenol

C38H44N2O6 (624.3199)

(3r,6s,9r,12s,15r)-3-(1h-indol-3-ylmethyl)-9-isopropyl-6,12,15-tris(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

C34H52N6O5 (624.3999)

{[(12e,14e,20e,22e)-1,2,3,5,7-pentahydroxy-28-(n-hydroxycarbamimidamido)-19-oxooctacosa-12,14,20,22-tetraen-1-ylidene]amino}acetic acid

C31H52N4O9 (624.3734)

(1s,5ar,7r,8s,9as,11ar)-1-[(2r,3r)-2,3-dihydroxy-6-methyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

C33H52O11 (624.3509)

2-[(1-{1-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]ethyl}-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-4-methoxy-6-methyloxane-3,5-diol

C34H56O10 (624.3873)

(1r,2s,4s,7s,8r,9s,12s,13r,16s,18s,19s)-16-hydroxy-19-{[(2r,4r,5r,6r)-5-hydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

C33H52O11 (624.3509)

(e,2z)-n-[(1e,3e,5r)-5-[(2r,4e,6e,10s,11s,12e,14s,18e)-11,14-dihydroxy-10-(c-hydroxycarbonimidoyloxy)-4-methyl-20-oxo-1-oxacycloicosa-4,6,12,18-tetraen-2-yl]-3-methylhexa-1,3-dien-1-yl]-3,5-dimethylhexa-2,5-dienimidic acid

C36H52N2O7 (624.3774)

n-[(2r,3s,4r)-4-[(9r,10r,14ar,16ar,17s,19s,20ar,20br)-17-(c-hydroxycarbonimidoyloxy)-19-methoxy-3,10,13,20b-tetramethyl-7-oxo-9h,10h,14ah,16ah,17h,18h,19h,20h,20ah-naphtho[2,1-h]oxacyclohexadecan-9-yl]-3-hydroxypentan-2-yl]ethanimidic acid

C36H52N2O7 (624.3774)

n-[(2r)-1-{[(5r,6e,8e,10e,13s,14s,15r,16e)-3,15-dihydroxy-5-methoxy-14,16-dimethyl-22,24-dioxo-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20-heptaen-13-yl]oxy}-1-oxopropan-2-yl]-4-methylpentanimidic acid

C35H48N2O8 (624.341)

7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

C33H52O11 (624.3509)

7'-(3,3-dimethyloxirane-2-carbonyl)-2',10a-dihydroxy-1,1,6-trimethyl-3a-(methylamino)-3,4,6,7,8,9,9a,10-octahydrospiro[cyclopenta[b]quinolizine-2,3'-indol]-8-yl 2-(dimethylamino)-3-methylbutanoate

C35H52N4O6 (624.3887)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-1-[(2r,6s)-7-hydroxy-6-methyl-5-methylideneheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C34H56O10 (624.3873)

16-hydroxy-19-({5-hydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

C33H52O11 (624.3509)

(20e)-7-butyl-11,16,23,24,25-pentahydroxy-10,19,21-trimethyl-15-methylidene-8,13,28,29-tetraoxatetracyclo[22.3.1.1³,⁶.0¹²,¹⁴]nonacos-20-ene-9,18-dione

C33H52O11 (624.3509)

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)

4-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-{[(1r)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}phenol

C38H44N2O6 (624.3199)

3-[(9e)-8-hydroxy-3-oxoheptadec-9-en-4,6-diyn-1-yl]-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1-benzopyran-2,4-dione

C41H52O5 (624.3815)

5-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-{[(1r)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}phenol

C38H44N2O6 (624.3199)

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4r,5s)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O11 (624.3509)

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14r)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)

n-{3-hydroxy-4-[17-(c-hydroxycarbonimidoyloxy)-19-methoxy-3,10,13,20b-tetramethyl-7-oxo-9h,10h,14ah,16ah,17h,18h,19h,20h,20ah-naphtho[2,1-h]oxacyclohexadecan-9-yl]pentan-2-yl}ethanimidic acid

C36H52N2O7 (624.3774)

5,8,14,17-tetrahydroxy-6,9,15,18-tetraisopropyl-3,12-bis(2-methylpropyl)-1,10-dioxa-4,7,13,16-tetraazacyclooctadeca-4,7,13,16-tetraene-2,11-dione

C32H56N4O8 (624.4098)

5-methyl-n-[1-oxo-1-({3,15,22-trihydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl}oxy)propan-2-yl]hexanimidic acid

C36H52N2O7 (624.3774)

(2r,3r,4s,5s,6r)-2-[(2s)-4-[(1s,2s,4s,6r,7s,8r,9s,12s,13r,14r,16r)-14,16-dihydroxy-6-methoxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O10 (624.3873)